The case pits a German biotech firm—CureVac, acquired by BioNTech in 2025—against U.S.-based Moderna. CureVac's own COVID vaccine achieved only 47% efficacy in Phase 3 trials and failed to reach market, while Moderna's Spikevax became a commercial success. The specific damages sought and Moderna's response remain undisclosed.
This filing is the latest escalation in a broader patent war among mRNA vaccine makers. BioNTech sued Moderna in 2026 over its mNEXSPIKE technology, while Moderna has previously sued Pfizer-BioNTech over vaccine patents. These disputes reflect unresolved intellectual property claims from pandemic-era vaccine development—a period when speed to market often outpaced formal licensing agreements. Practitioners should monitor whether this case becomes a bellwether for how courts value foundational mRNA patents and what royalty frameworks emerge for the technology.